Mark W Tenforde

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6560048/publications.pdf

Version: 2024-02-01

49 papers 4,266 citations

331538 21 h-index 214721 47 g-index

52 all docs 52 docs citations

times ranked

52

7270 citing authors

#	Article	IF	CITATIONS
1	Point Prevalence Estimates of Activity-Limiting Long-term Symptoms Among United States Adults ≥1 Month After Reported Severe Acute Respiratory Syndrome Coronavirus 2 Infection, 1 November 2021. Journal of Infectious Diseases, 2023, 227, 855-863.	1.9	13
2	BNT162b2 Protection against the Omicron Variant in Children and Adolescents. New England Journal of Medicine, 2022, 386, 1899-1909.	13.9	173
3	Human Herpesvirus-6 Detection in Cerebrospinal Fluid on the BioFire FilmArray Meningitis/Encephalitis Panel in a High Human Immunodeficiency Virus-Prevalence African Setting. Open Forum Infectious Diseases, 2022, 9, .	0.4	3
4	Ascertainment of vaccination status by selfâ€report versus source documentation: Impact on measuring COVIDâ€19 vaccine effectiveness. Influenza and Other Respiratory Viruses, 2022, 16, 1101-1111.	1.5	15
5	Influenza Vaccine Effectiveness in Inpatient and Outpatient Settings in the United States, 2015–2018. Clinical Infectious Diseases, 2021, 73, 386-392.	2.9	41
6	Prevalence and Sequelae of Cryptococcal Antigenemia in Antiretroviral Therapy–Experienced Populations: An Evaluation of Reflex Cryptococcal Antigen Screening in Botswana. Clinical Infectious Diseases, 2021, 72, 1745-1754.	2.9	10
7	Outcomes of Reflex Cryptococcal Antigen (CrAg) Screening in Human Immunodeficiency Virus (HIV)-Positive Patients With CD4 Counts of 100–200 Cells/µL in Botswana. Clinical Infectious Diseases, 2021, 72, 1635-1638.	2.9	7
8	Exposures in adult outpatients with COVIDâ€19 infection during early community transmission, Tennessee. Influenza and Other Respiratory Viruses, 2021, 15, 175-177.	1.5	2
9	The prevalence of laboratory-confirmed <i>Pneumocystis jirovecii</i> in HIV-infected adults in Africa: A systematic review and meta-analysis. Medical Mycology, 2021, 59, 802-812.	0.3	11
10	Cost-effectiveness of cryptococcal antigen screening at CD4 counts of 101–200 cells/µL in Botswana. Wellcome Open Research, 2021, 6, 55.	0.9	0
11	Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1074.	3.8	617
12	Influenza Vaccine Effectiveness for Prevention of Severe Influenza-Associated Illness Among Adults in the United States, 2019–2020: A Test-Negative Study. Clinical Infectious Diseases, 2021, 73, 1459-1468.	2.9	17
13	Data-driven clustering identifies features distinguishing multisystem inflammatory syndrome from acute COVID-19 in children and adolescents. EClinicalMedicine, 2021, 40, 101112.	3.2	23
14	Influenza Vaccine Effectiveness Against Hospitalization in the United States, 2019–2020. Journal of Infectious Diseases, 2021, 224, 813-820.	1.9	30
15	Differentiating severe and non-severe lower respiratory tract illness in patients hospitalized with influenza: Development of the Influenza Disease Evaluation and Assessment of Severity (IDEAS) scale. PLoS ONE, 2021, 16, e0258482.	1.1	2
16	Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA - Journal of the American Medical Association, 2021, 326, 2043.	3.8	458
17	Empirical tuberculosis therapy in advanced HIV disease. Lancet HIV, the, 2020, 7, e3-e5.	2.1	1
18	Reduction in Baseline CD4 Count Testing Following Human Immunodeficiency Virus "Treat All― Adoption in Uganda. Clinical Infectious Diseases, 2020, 71, 2497-2499.	2.9	6

#	Article	IF	CITATIONS
19	Diagnostic Accuracy of the Biosynex CryptoPS Cryptococcal Antigen Semiquantitative Lateral Flow Assay in Patients with Advanced HIV Disease. Journal of Clinical Microbiology, 2020, 59, .	1.8	10
20	Evaluation of a Novel Semiquantitative Cryptococcal Antigen Lateral Flow Assay in Patients with Advanced HIV Disease. Journal of Clinical Microbiology, 2020, 58, .	1.8	19
21	Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. New England Journal of Medicine, 2020, 383, 334-346.	13.9	2,006
22	Mortality from HIVâ€associated meningitis in subâ€Saharan Africa: a systematic review and metaâ€analysis. Journal of the International AIDS Society, 2020, 23, e25416.	1.2	39
23	Early Season Pediatric Influenza B/Victoria Virus Infections Associated with a Recently Emerged Virus Subclade — Louisiana, 2019. Morbidity and Mortality Weekly Report, 2020, 69, 40-43.	9.0	23
24	Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus–associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. Clinical Infectious Diseases, 2019, 68, 393-401.	2.9	62
25	HIV-associated cryptococcal meningitis: ongoing challenges and new opportunities. Lancet Infectious Diseases, The, 2019, 19, 793-794.	4.6	5
26	Mortality in adult patients with culture-positive and culture-negative meningitis in the Botswana national meningitis survey: a prevalent cohort study. Lancet Infectious Diseases, The, 2019, 19, 740-749.	4.6	25
27	Epidemiology of adult meningitis during antiretroviral therapy scale-up in southern Africa: Results from the Botswana national meningitis survey. Journal of Infection, 2019, 79, 212-219.	1.7	15
28	Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis. PLoS Medicine, 2019, 16, e1002907.	3.9	91
29	Rapid antiretroviral therapy initiation in low- and middle-income countries: A resource-based approach. PLoS Medicine, 2019, 16, e1002723.	3.9	16
30	Low-cerebrospinal fluid white cell counts and mortality in HIV-associated pneumococcal meningitis. Aids, 2019, 33, 1539-1541.	1.0	1
31	Causes of Pediatric Meningitis in Botswana: Results From a 16-Year National Meningitis Audit. Pediatric Infectious Disease Journal, 2019, 38, 906-911.	1.1	8
32	Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in Botswana. Wellcome Open Research, 2019, 4, 144.	0.9	12
33	Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in Botswana. Wellcome Open Research, 2019, 4, 144.	0.9	9
34	Poor specificity of urinary cryptococcal antigen testing. HIV Medicine, 2018, 19, e47-e48.	1.0	3
35	High Mortality in HIV-Associated Cryptococcal Meningitis Patients Treated With Amphotericin B–Based Therapy Under Routine Care Conditions in Africa. Open Forum Infectious Diseases, 2018, 5, ofy267.	0.4	30
36	Neurological Sequelae of Adult Meningitis in Africa: A Systematic Literature Review. Open Forum Infectious Diseases, 2018, 5, ofx246.	0.4	12

#	Article	IF	Citations
37	Treatment for HIV-associated cryptococcal meningitis. The Cochrane Library, 2018, 2018, CD005647.	1.5	33
38	Maternal Hepatitis B Infection and Pregnancy Outcomes in the United States: A Population-Based Cohort Study. Open Forum Infectious Diseases, 2018, 5, ofy134.	0.4	32
39	Advanced Human Immunodeficiency Virus Disease in Botswana Following Successful Antiretroviral Therapy Rollout: Incidence of and Temporal Trends in Cryptococcal Meningitis. Clinical Infectious Diseases, 2017, 65, 779-786.	2.9	56
40	Vitamin A and D Deficiencies Associated With Incident Tuberculosis in HIV-Infected Patients Initiating Antiretroviral Therapy in Multinational Case-Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, e71-e79.	0.9	33
41	Modulating host immune responses to fight invasive fungal infections. Current Opinion in Microbiology, 2017, 40, 95-103.	2.3	32
42	Immune correlates of HIV-associated cryptococcal meningitis. PLoS Pathogens, 2017, 13, e1006207.	2.1	19
43	Safety and clinical response of intraventricular caspofungin for Scedosporium apiospermum complex central nervous system infection. Medical Mycology Case Reports, 2016, 13, 1-4.	0.7	7
44	HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings. Current Clinical Microbiology Reports, 2016, 3, 92-102.	1.8	21
45	C-Reactive Protein (CRP), Interferon Gamma-Inducible Protein 10 (IP-10), and Lipopolysaccharide (LPS) Are Associated with Risk of Tuberculosis after Initiation of Antiretroviral Therapy in Resource-Limited Settings. PLoS ONE, 2015, 10, e0117424.	1.1	23
46	Preventing Cryptococcosisâ€"Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy. Current Tropical Medicine Reports, 2015, 2, 81-89.	1.6	38
47	The Association Between Personal Health Record Use and Diabetes Quality Measures. Journal of General Internal Medicine, 2012, 27, 420-424.	1.3	108
48	The value of personal health records for chronic disease management: what do we know?. Family Medicine, 2011, 43, 351-4.	0.3	49
49	Cost-effectiveness of cryptococcal antigen screening at CD4 counts of 101–200 cells/ÂμL in Botswana. Wellcome Open Research, 0, 6, 55.	0.9	0